These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23845217)

  • 1. Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity.
    Dao P; Jarray R; Le Coq J; Lietha D; Loukaci A; Lepelletier Y; Hadj-Slimane R; Garbay C; Raynaud F; Chen H
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4552-6. PubMed ID: 23845217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity.
    Dao P; Smith N; Tomkiewicz-Raulet C; Yen-Pon E; Camacho-Artacho M; Lietha D; Herbeuval JP; Coumoul X; Garbay C; Chen H
    J Med Chem; 2015 Jan; 58(1):237-51. PubMed ID: 25180654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A structure-activity relationship study of 1,2,4-triazolo[1,5-a][1,3,5]triazin-5,7-dione and its 5-thioxo analogues on anti-thymidine phosphorylase and associated anti-angiogenic activities.
    Bera H; Tan BJ; Sun L; Dolzhenko AV; Chui WK; Chiu GN
    Eur J Med Chem; 2013 Sep; 67():325-34. PubMed ID: 23871912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of mixed type thymidine phosphorylase inhibitors endowed with antiangiogenic properties: synthesis, pharmacological evaluation and molecular docking study of 2-thioxo-pyrazolo[1,5-a][1,3,5]triazin-4-ones. Part II.
    Bera H; Ojha Pk; Tan BJ; Sun L; Dolzhenko AV; Chui WK; Chiu GN
    Eur J Med Chem; 2014 May; 78():294-303. PubMed ID: 24686016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors.
    Borzilleri RM; Cai ZW; Ellis C; Fargnoli J; Fura A; Gerhardt T; Goyal B; Hunt JT; Mortillo S; Qian L; Tokarski J; Vyas V; Wautlet B; Zheng X; Bhide RS
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1429-33. PubMed ID: 15713401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focal adhesion kinase inhibitors are potent anti-angiogenic agents.
    Cabrita MA; Jones LM; Quizi JL; Sabourin LA; McKay BC; Addison CL
    Mol Oncol; 2011 Dec; 5(6):517-26. PubMed ID: 22075057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2.
    Choi HS; Wang Z; Richmond W; He X; Yang K; Jiang T; Karanewsky D; Gu XJ; Zhou V; Liu Y; Che J; Lee CC; Caldwell J; Kanazawa T; Umemura I; Matsuura N; Ohmori O; Honda T; Gray N; He Y
    Bioorg Med Chem Lett; 2006 May; 16(10):2689-92. PubMed ID: 16524731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity.
    Dao P; Lietha D; Etheve-Quelquejeu M; Garbay C; Chen H
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1727-1730. PubMed ID: 28284808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure elucidation of novel fused 1,2,4-triazine derivatives as potent inhibitors targeting CYP1A1 activity.
    El Massry AM; Asal AM; Khattab SN; Haiba NS; Awney HA; Helmy M; Langer V; Amer A
    Bioorg Med Chem; 2012 Apr; 20(8):2624-37. PubMed ID: 22414679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Hydroxy-4,6-diamino-[1,3,5]triazines: a novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors.
    Baindur N; Chadha N; Brandt BM; Asgari D; Patch RJ; Schalk-Hihi C; Carver TE; Petrounia IP; Baumann CA; Ott H; Manthey C; Springer BA; Player MR
    J Med Chem; 2005 Mar; 48(6):1717-20. PubMed ID: 15771417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of Yangzheng Xiaoji on angiogenesis and the role of the focal adhesion kinase pathway.
    Jiang WG; Ye L; Ji K; Frewer N; Ji J; Mason MD
    Int J Oncol; 2012 Nov; 41(5):1635-42. PubMed ID: 22971748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic concentrations of digitoxin inhibit endothelial focal adhesion kinase and angiogenesis induced by different growth factors.
    Trenti A; Zulato E; Pasqualini L; Indraccolo S; Bolego C; Trevisi L
    Br J Pharmacol; 2017 Sep; 174(18):3094-3106. PubMed ID: 28688145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II induces focal adhesion kinase/paxillin phosphorylation and cell migration in human umbilical vein endothelial cells.
    Montiel M; de la Blanca EP; Jiménez E
    Biochem Biophys Res Commun; 2005 Feb; 327(4):971-8. PubMed ID: 15652490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of novel curcumin mimics with asymmetrical units and their anti-angiogenic activity.
    Woo HB; Shin WS; Lee S; Ahn CM
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3782-6. PubMed ID: 15993583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based discovery of focal adhesion kinase inhibitors.
    Grädler U; Bomke J; Musil D; Dresing V; Lehmann M; Hölzemann G; Greiner H; Esdar C; Krier M; Heinrich T
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5401-9. PubMed ID: 23973211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regioselective synthesis of 5- and 6-methoxybenzimidazole-1,3,5-triazines as inhibitors of phosphoinositide 3-kinase.
    Miller MS; Pinson JA; Zheng Z; Jennings IG; Thompson PE
    Bioorg Med Chem Lett; 2013 Feb; 23(3):802-5. PubMed ID: 23265896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3.
    Harikrishnan LS; Kamau MG; Wan H; Inghrim JA; Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Lombardo LJ; Poss MA; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Baldwin KF; Lippy J; Nirschl DS; Qiu R; Miller AV; Khan J; Sack JS; Purandare AV
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1425-8. PubMed ID: 21282055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-angiogenic effects of thioridazine involving the FAK-mTOR pathway.
    Byun HJ; Lee JH; Kim BR; Kang S; Dong SM; Park MS; Lee SH; Park SH; Rho SB
    Microvasc Res; 2012 Nov; 84(3):227-34. PubMed ID: 23022044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.
    Hodous BL; Geuns-Meyer SD; Hughes PE; Albrecht BK; Bellon S; Bready J; Caenepeel S; Cee VJ; Chaffee SC; Coxon A; Emery M; Fretland J; Gallant P; Gu Y; Hoffman D; Johnson RE; Kendall R; Kim JL; Long AM; Morrison M; Olivieri PR; Patel VF; Polverino A; Rose P; Tempest P; Wang L; Whittington DA; Zhao H
    J Med Chem; 2007 Feb; 50(4):611-26. PubMed ID: 17253678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
    Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
    Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.